A seroprevalence study of poliovirus antibody in the population of northern Greece

Clinical Microbiology and Infection

Volumn 11, Issue 1, 2005, Pages 68-71

  Frantzidou, Filanthi ^a   Diza, E ^a   Halkia, D ^a   Antoniadis, A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Greece; Immunity; Poliovirus; Seroprevalence; Vaccination

Indexed keywords

POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; CONFIDENCE INTERVAL; FEMALE; GREECE; HUMAN; IMMUNITY; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEROPREVALENCE; VACCINATION;

HUMAN POLIOVIRUS 3; POLIOVIRUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 13644254157     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00998.x     Document Type: Article

References (20)

1. Anonymous. Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis 2000-2001. Wkly Epidemiol Rec 2001; 36: 274-277.
2. Centers for Disease Control. Public heath dispatch. Outbreak of poliomyelitis - Dominican Republic and Haiti. MMWR 2000; 49 1094-1103.
3. Schrope M. Plans to eradicate polio hit by virus outbreak in Bulgaria. Nature 2001; 411: 405.
4. Frantzidou-Adamopoulou F. Poliomyelitis cases in Northern Greece 1976-1990. Eur J Epidemiol 1992; 8: 112-113.
5. Prevots DR, Ciofi degli Atti ML, Sallaband A et al. Outbreak of paralytic poliomyelitis in Albania 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis 1998; 26: 412-425.
6. Fiore L, Genovese D, Diamanti E et al. Antigenic and molecular characterization of wild type 1 poliovirus causing outbreaks of poliomyelitis in Albania and neighboring countries in 1996. J Clin Microbiol 1998; 36: 1912-1918.
7. Stefanou TH. Preventive medicine and the Ministry of Social Services. Hell Arm Forces Med Rev 1980; 14: 55-69.
8. Panagiotopoulos; T, Valassi-Adam E, Sarafidou E et al. Greek study on vaccination coverage. Arch Hell Med 1999; 16: 154-162.
9. Menci C, Pregliasco F. Poliomyelitis: present epidemiological situation and vaccination problems. Clin Diagn Lab Immunol 1998; 5: 278-280.
10. National Statistical Services of Greece. Statistical yearbook of Greece. Athens: National Statistical Services, 2001.
11. World Health Organization. Manual for the virological investigation of polio. WHO/EPI/GEN 97.01. Geneva: WHO, 1997.
12. Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis 2000; 182: 1-5.
13. Green MS, Handsher R, Cohen D et al. Age differences in immunity against wild and vaccine strains of poliovirus prior to the 1988 outbreak in Israel and response to booster immunization. Vaccine 1993; 11: 75-81.
14. Swartz TA, Handsher R, Manor Y et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine 1998; 16: 582-584.
15. Conyn-van Spaendonck MAE, Hannik CA, Bijkerk H et al. Immunity status for poliomyelitis, rubella, and morbilli in the Dutch population of 10 years or older in 1980: a serological survey. Ned Tijdschr Geneeskd 1984; 128: 1884-1889.
16. White PM, Green J. Prevalence of antibody to polio-viruses in England and Wales 1984-6. BMJ 1986; 293: 1153-1155.
17. Diedrich S, Claus H, Schreier E. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis 2002; 2: 2-7.
18. Conyn-van Spaendonck MAE, de Melke HE, Abbink F et al. Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 2001; 153: 207-212.
19. Mastroeni I, Patii AM, Fabrizi A et al. Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 1997; 15: 745-750.
20. Aylward RB, Porta D, Fiore L et al. Unimmunized gypsy populations and implications for the eradication of poliomyelitis in Europe. J Infect Dis 1997; 175 (Suppl 1): S86-S88.